# The Evaluation of the Efficacy and Safety of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment (MCI)

> **NCT00293176** · PHASE4 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 821 (actual)

## Conditions studied

- Memory Loss

## Interventions

- **DRUG:** Donepezil Hydrochloride
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00293176
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12
- **Primary completion:** 2007-03
- **Final completion:** 2007-03
- **Target enrollment:** 821 (ACTUAL)
- **Last updated:** 2011-04-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00293176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00293176, "The Evaluation of the Efficacy and Safety of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment (MCI)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00293176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*